GSK1349572 + Rifampin + Rifabutin
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Infection, Human Immunodeficiency Virus
Conditions
Infection, Human Immunodeficiency Virus
Trial Timeline
May 1, 2011 → Dec 1, 2011
NCT ID
NCT01231542About GSK1349572 + Rifampin + Rifabutin
GSK1349572 + Rifampin + Rifabutin is a phase 1 stage product being developed by Shionogi for Infection, Human Immunodeficiency Virus. The current trial status is completed. This product is registered under clinical trial identifier NCT01231542. Target conditions include Infection, Human Immunodeficiency Virus.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01231542 | Phase 1 | Completed |
Competing Products
20 competing products in Infection, Human Immunodeficiency Virus